UK-based biopharmaceutical firm Arecor has announced that its ultra-rapid acting insulin candidate, AT247, demonstrated encouraging pharmacokinetic and pharmacodynamic profiles in a Phase I clinical trial.

AT247 was compared to Novo Nordisk’s NovoRapid and Fiasp during the trial.

The ultra-rapid acting insulin formulation is intended for meal-time administration. It is designed to speed up insulin absorption for effective blood glucose levels management.

Arecor said that the therapy has the potential to boost postprandial glucose control, allow flexible insulin dosing and avoid hypo, as well as hyperglycaemia.

The double-blind, randomised, cross-over, three-period Phase I trial was conducted at The Medical University of Graz and Joanneum Research in Austria to assess AT247’s pharmacokinetic and pharmacodynamic profiles in Type 1 diabetes patients.

Arecor CEO Sarah Howell said: “In addition to the potential to improve blood glucose control after meals, AT247 may play a critical role in advancing artificial pancreas systems.

“With AT247’s favourable profile over current treatments, we believe that our products have the potential to advance the diabetic treatment landscape. We look forward to reporting the full data from this Phase I study in due course.”

The company submitted a clinical trial application for the Phase I study in January this year and secured regulatory approval from the Austrian Federal Office for Safety in Health Care in March.

Patient dosing was commenced in May and concluded in October along with all patient visits.

Following the completion of the Phase I trial, the company intends to further study the ultra-rapid acting insulin product in the clinical setting next year under its accelerated development pathway.

Arecor is also developing an ultra-concentrated rapid-acting insulin product to help treat diabetes.